Lumiracoxib is a synthetic non-steroidal anti-inflammatory drug (NSAID) belonging to the selective cyclooxygenase-2 (COX-2) inhibitor class. It was developed for the management of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions.
Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2), an enzyme involved in the production of prostaglandins that contribute to pain and inflammation. Its selectivity for COX-2 distinguishes it pharmacologically from traditional non-selective NSAIDs.
Lumiracoxib is a synthetic small-molecule compound with the molecular formula C13H8Cl2FNO2 and a molecular weight of approximately 296.12 g/mol. Its CAS Number is 61618-27-7.
The compound contains a substituted phenylacetic acid structure with chlorine and fluorine substituents. Its physicochemical characteristics support its classification as a selective COX-2 inhibitor.
Lumiracoxib selectively inhibits the COX-2 enzyme, reducing the conversion of arachidonic acid into prostaglandins.
Prostaglandins play an important role in the development of pain, inflammation and fever. By decreasing prostaglandin synthesis, lumiracoxib provides analgesic and anti-inflammatory effects.
Lumiracoxib was developed primarily for the symptomatic treatment of osteoarthritis pain and other acute or chronic inflammatory pain conditions.
Its regulatory status and availability vary between countries, and its use is subject to applicable regulatory requirements.
Lumiracoxib API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
Chromatographic and spectroscopic techniques may be used for identity, assay and purity determination. Appropriate controls should be established for process-related impurities and degradation products.
Acceptance criteria should be based on the applicable manufacturer's drug-substance specification, Certificate of Analysis and relevant pharmacopoeial and regulatory requirements.
Lumiracoxib should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. It should be protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Lumiracoxib API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Lumiracoxib API is available for qualified pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.5 – 6.5 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |